Dosing & Uses
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Other Indications & Uses
Peptic ulcer disease, abdominal cramps, spastic bladder, cystitis, pylorospasm, IBS, biliary and renal colic, urinary incontinence, Parkinsonism, acute rhinitis, sialorrhea, hyperhidrosis, cholinergic poisoning
Heat prostration may be caused due to suppression of sweating
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
<12 years: Safety and efficacy not established
12 years or older: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Avoid; high incidence of anticholinergic effects; avoid except in short-term situations to decrease secretions (Beers Criteria)
Excessive gastric secretion: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
Frequency Not Defined
Headache
Nervousness
Blurred vision
Cycloplegia/mydriasis
Increased IOP
Tachycardia
Urinary retention
Xerostomia
Warnings
Contraindications
Glaucoma, obstructive uropathy, GI obstruction, myasthenia gravis, toxic megacolon, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis
Cautions
Autonomic neuropathy, hiatal hernia, reflux esophagitis, renal dz, hyperthyroidism, tachyarrhythmia, CHF, salivary secretion disorder, BPH
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in breast milk, use caution (may suppress lactation)
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Parasympatholytic, atropine-like effects, especially peripherally, blocks the action of ACh at parasympathetic sites in smooth muscle, secretory glands, and CNS
Pharmacokinetics
Absorption: rapid & complete
Half-Life: 2-3.5 hr
Protein Bound: 50%
Metabolism: Partially hydrolyzed to tropic acid & tropine
Excretion: Urine
Vd
- Adults: 1.2-1.9 L/kg
- Children 3.5-16 yo: 1.1-3.7 L/kg
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.